Autologous stem cells cut insulin requirements in type 2 diabetes

07/1/2013 | Medical News Today

A study in Cell Transplantation found type 2 diabetes patients who received autologous bone marrow stem cells required lower insulin doses compared with those in the control group. Longer-duration studies with a larger number of participants will be needed to establish the efficacy of stem cell treatment in diabetes, researchers said.

View Full Article in:

Medical News Today

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC